PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

Authors:

Abstract
No abstract available
Funding Information
  • The Royal Marsden
  • The Institute of Cancer Research
  • ECMC Combinations Alliance
  • The Rosetrees Trust
  • National Institute for Health Research
  • Biomedical Research Centre

This publication has 14 references indexed in Scilit: